JP2018536023A - 単純ヘルペスウイルスワクチン - Google Patents

単純ヘルペスウイルスワクチン Download PDF

Info

Publication number
JP2018536023A
JP2018536023A JP2018541090A JP2018541090A JP2018536023A JP 2018536023 A JP2018536023 A JP 2018536023A JP 2018541090 A JP2018541090 A JP 2018541090A JP 2018541090 A JP2018541090 A JP 2018541090A JP 2018536023 A JP2018536023 A JP 2018536023A
Authority
JP
Japan
Prior art keywords
hsv
vaccine
subject
rna
antigenic polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018541090A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018536023A5 (https=
Inventor
ジュゼッペ チャラメッラ，
ジュゼッペ チャラメッラ，
シヌ ジョン，
シヌ ジョン，
アンドリュー ジェイ． ベット，
アンドリュー ジェイ． ベット，
ダニーロ アール． カシミロ，
ダニーロ アール． カシミロ，
Original Assignee
モデルナティーエックス， インコーポレイテッド
モデルナティーエックス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by モデルナティーエックス， インコーポレイテッド, モデルナティーエックス， インコーポレイテッド filed Critical モデルナティーエックス， インコーポレイテッド
Publication of JP2018536023A publication Critical patent/JP2018536023A/ja
Publication of JP2018536023A5 publication Critical patent/JP2018536023A5/ja
Priority to JP2021204272A priority Critical patent/JP2022037134A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2018541090A 2015-10-22 2016-10-21 単純ヘルペスウイルスワクチン Pending JP2018536023A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021204272A JP2022037134A (ja) 2015-10-22 2021-12-16 単純ヘルペスウイルスワクチン

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201562245159P 2015-10-22 2015-10-22
US201562245031P 2015-10-22 2015-10-22
US62/245,031 2015-10-22
US62/245,159 2015-10-22
US201562247576P 2015-10-28 2015-10-28
US62/247,576 2015-10-28
US201562248252P 2015-10-29 2015-10-29
US62/248,252 2015-10-29
PCT/US2016/058322 WO2017070623A1 (en) 2015-10-22 2016-10-21 Herpes simplex virus vaccine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021204272A Division JP2022037134A (ja) 2015-10-22 2021-12-16 単純ヘルペスウイルスワクチン

Publications (2)

Publication Number Publication Date
JP2018536023A true JP2018536023A (ja) 2018-12-06
JP2018536023A5 JP2018536023A5 (https=) 2020-08-13

Family

ID=58558127

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018541090A Pending JP2018536023A (ja) 2015-10-22 2016-10-21 単純ヘルペスウイルスワクチン
JP2021204272A Pending JP2022037134A (ja) 2015-10-22 2021-12-16 単純ヘルペスウイルスワクチン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021204272A Pending JP2022037134A (ja) 2015-10-22 2021-12-16 単純ヘルペスウイルスワクチン

Country Status (19)

Country Link
US (2) US20180303929A1 (https=)
EP (1) EP3365009A4 (https=)
JP (2) JP2018536023A (https=)
KR (1) KR20180096593A (https=)
CN (1) CN108472355A (https=)
AU (2) AU2016342049B2 (https=)
BR (1) BR112018008090A2 (https=)
CA (1) CA3002822A1 (https=)
CL (1) CL2018001056A1 (https=)
CO (1) CO2018005258A2 (https=)
EA (1) EA201890999A1 (https=)
IL (1) IL258833A (https=)
MA (1) MA46024A (https=)
MX (1) MX2018004918A (https=)
PE (1) PE20181531A1 (https=)
PH (1) PH12018500855A1 (https=)
SG (1) SG11201803365RA (https=)
TN (1) TN2018000155A1 (https=)
WO (1) WO2017070623A1 (https=)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
SG10201912038TA (en) 2014-04-23 2020-02-27 Modernatx Inc Nucleic acid vaccines
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
EP3324979B1 (en) 2015-07-21 2022-10-12 ModernaTX, Inc. Infectious disease vaccines
WO2017020026A1 (en) 2015-07-30 2017-02-02 Modernatx, Inc. Concatemeric peptide epitopes rnas
WO2017031232A1 (en) 2015-08-17 2017-02-23 Modernatx, Inc. Methods for preparing particles and related compositions
US20180289792A1 (en) 2015-10-22 2018-10-11 ModernaTX. Inc. Sexually transmitted disease vaccines
EP3364981A4 (en) 2015-10-22 2019-08-07 ModernaTX, Inc. VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS
CA3002912A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Nucleic acid vaccines for varicella zoster virus (vzv)
EP3364949A4 (en) 2015-10-22 2019-07-31 ModernaTX, Inc. CANCER VACCINES
TW201729835A (zh) 2015-10-22 2017-09-01 現代公司 呼吸道病毒疫苗
EP3364950A4 (en) 2015-10-22 2019-10-23 ModernaTX, Inc. VACCINES AGAINST TROPICAL DISEASES
HRP20220652T1 (hr) 2015-12-10 2022-06-24 Modernatx, Inc. Pripravci i postupci unosa terapijskih sredstava
US10465190B1 (en) 2015-12-23 2019-11-05 Modernatx, Inc. In vitro transcription methods and constructs
MA45052A (fr) 2016-05-18 2019-03-27 Modernatx Inc Polynucléotides codant pour jagged1 pour le traitement du syndrome d'alagille
KR20230074598A (ko) 2016-05-18 2023-05-30 모더나티엑스, 인크. 릴랙신을 인코딩하는 폴리뉴클레오타이드
CN116837052A (zh) 2016-09-14 2023-10-03 摩登纳特斯有限公司 高纯度rna组合物及其制备方法
MA46584A (fr) 2016-10-21 2019-08-28 Modernatx Inc Vaccin contre le cytomégalovirus humain
WO2018089851A2 (en) 2016-11-11 2018-05-17 Modernatx, Inc. Influenza vaccine
WO2018107088A2 (en) 2016-12-08 2018-06-14 Modernatx, Inc. Respiratory virus nucleic acid vaccines
WO2018111967A1 (en) 2016-12-13 2018-06-21 Modernatx, Inc. Rna affinity purification
WO2018151816A1 (en) 2017-02-16 2018-08-23 Modernatx, Inc. High potency immunogenic compositions
US11752206B2 (en) * 2017-03-15 2023-09-12 Modernatx, Inc. Herpes simplex virus vaccine
US11045540B2 (en) 2017-03-15 2021-06-29 Modernatx, Inc. Varicella zoster virus (VZV) vaccine
EP3595713A4 (en) 2017-03-15 2021-01-13 ModernaTX, Inc. RESPIRATORY SYNCYTIAL VIRUS Vaccine
WO2018170245A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Broad spectrum influenza virus vaccine
MA47790A (fr) 2017-03-17 2021-05-05 Modernatx Inc Vaccins à base d'arn contre des maladies zoonotiques
WO2018187590A1 (en) 2017-04-05 2018-10-11 Modernatx, Inc. Reduction or elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins
US11160860B2 (en) 2017-04-26 2021-11-02 Merck Sharp & Dohme Corp. HSV antigenic peptides and HSV protein vaccines
MA49463A (fr) * 2017-04-26 2021-05-05 Modernatx Inc Vaccin contre le virus de l'herpès simplex
US11786607B2 (en) 2017-06-15 2023-10-17 Modernatx, Inc. RNA formulations
CN111246854A (zh) * 2017-08-17 2020-06-05 宾夕法尼亚大学理事会 编码单纯疱疹病毒糖蛋白的修饰mrna疫苗及其用途
WO2019036685A1 (en) 2017-08-18 2019-02-21 Modernatx, Inc. METHODS FOR HPLC ANALYSIS
WO2019036683A1 (en) 2017-08-18 2019-02-21 Modernatx, Inc. ANALYTICAL METHODS BY HPLC
ES2983060T3 (es) 2017-08-18 2024-10-21 Modernatx Inc Variantes de ARN polimerasa
WO2019046809A1 (en) 2017-08-31 2019-03-07 Modernatx, Inc. METHODS OF MANUFACTURING LIPID NANOPARTICLES
EP3681514A4 (en) 2017-09-14 2021-07-14 ModernaTX, Inc. RNA VACZINE AGAINST ZIKA VIRUS
WO2019148101A1 (en) 2018-01-29 2019-08-01 Modernatx, Inc. Rsv rna vaccines
AU2019345067A1 (en) 2018-09-19 2021-04-08 Modernatx, Inc. High-purity peg lipids and uses thereof
MA53650A (fr) 2018-09-19 2021-07-28 Modernatx Inc Lipides peg et leurs utilisations
CN113271926A (zh) 2018-09-20 2021-08-17 摩登纳特斯有限公司 脂质纳米颗粒的制备及其施用方法
US11351242B1 (en) 2019-02-12 2022-06-07 Modernatx, Inc. HMPV/hPIV3 mRNA vaccine composition
CN109701008B (zh) * 2019-02-18 2022-06-21 山东兴瑞生物科技有限公司 针对单纯疱疹病毒的治疗性dc复合疫苗及其制备方法
CN113795579A (zh) 2019-02-20 2021-12-14 摩登纳特斯有限公司 用于共转录加帽的rna聚合酶变体
US11851694B1 (en) 2019-02-20 2023-12-26 Modernatx, Inc. High fidelity in vitro transcription
CA3132975A1 (en) 2019-03-11 2020-09-17 Modernatx, Inc. Fed-batch in vitro transcription process
EP3938379A4 (en) 2019-03-15 2023-02-22 ModernaTX, Inc. Hiv rna vaccines
EP3999093A4 (en) * 2019-07-19 2023-11-22 Merck Sharp & Dohme LLC ANTIGENIC E GLYCOPROTEIN POLYPEPTIDES, COMPOSITIONS AND METHODS OF USE THEREOF
KR20220035457A (ko) * 2019-07-21 2022-03-22 글락소스미스클라인 바이오로지칼즈 에스.에이. 치료 바이러스 백신
KR20230013237A (ko) 2020-03-09 2023-01-26 다이나박스 테크놀로지 코퍼레이션 Tlr9 효능제를 포함하는 대상포진 백신
WO2021197589A1 (en) * 2020-03-31 2021-10-07 BioNTech SE Treatment involving non-immunogenic rna for antigen vaccination
EP3901261A1 (en) 2020-04-22 2021-10-27 BioNTech RNA Pharmaceuticals GmbH Coronavirus vaccine
KR20230034333A (ko) 2020-07-02 2023-03-09 라이프 테크놀로지스 코포레이션 트리뉴클레오티드 캡 유사체, 제조 및 이의 용도
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
US12329811B2 (en) 2021-01-11 2025-06-17 Modernatx, Inc. Seasonal RNA influenza virus vaccines
US11524023B2 (en) 2021-02-19 2022-12-13 Modernatx, Inc. Lipid nanoparticle compositions and methods of formulating the same
JP2024512394A (ja) * 2021-03-11 2024-03-19 レッドバイオテック・アーゲー Ｈｓｖを処置するためのワクチン組成物及び方法
US20220363937A1 (en) 2021-05-14 2022-11-17 Armstrong World Industries, Inc. Stabilization of antimicrobial coatings
MX2024002726A (es) 2021-09-03 2024-03-20 CureVac SE Nuevas nanoparticulas lipidicas para la administracion de acidos nucleicos.
WO2023073228A1 (en) 2021-10-29 2023-05-04 CureVac SE Improved circular rna for expressing therapeutic proteins
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
EP4444345A2 (en) 2021-12-08 2024-10-16 ModernaTX, Inc. Herpes simplex virus mrna vaccines
US12529047B1 (en) 2021-12-21 2026-01-20 Modernatx, Inc. mRNA quantification methods
CA3242744A1 (en) * 2022-01-27 2023-08-03 The Trustees Of The University Of Pennsylvania Pharmaceutical compositions for the administration of herpes simplex virus antigens and associated methods
US20250099614A1 (en) 2022-01-28 2025-03-27 CureVac SE Nucleic acid encoded transcription factor inhibitors
WO2023227608A1 (en) 2022-05-25 2023-11-30 Glaxosmithkline Biologicals Sa Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide
WO2024002985A1 (en) 2022-06-26 2024-01-04 BioNTech SE Coronavirus vaccine
WO2024089638A1 (en) 2022-10-28 2024-05-02 Glaxosmithkline Biologicals Sa Nucleic acid based vaccine
WO2024125597A1 (en) 2022-12-14 2024-06-20 Providence Therapeutics Holdings Inc. Compositions and methods for infectious diseases
CN118217388A (zh) * 2022-12-19 2024-06-21 南京奥罗生物科技有限公司 单纯疱疹病毒疫苗及其应用
WO2024163465A1 (en) 2023-01-30 2024-08-08 Modernatx, Inc. Epstein-barr virus mrna vaccines
KR20250153298A (ko) 2023-03-08 2025-10-24 큐어백 에스이 핵산 전달을 위한 신규의 지질 나노입자 제형
WO2024215721A1 (en) 2023-04-10 2024-10-17 Modernatx, Inc. Lyme disease vaccines
WO2024230934A1 (en) 2023-05-11 2024-11-14 CureVac SE Therapeutic nucleic acid for the treatment of ophthalmic diseases
CN121772938A (zh) * 2023-08-03 2026-03-31 百欧恩泰欧洲股份公司 用于递送单纯疱疹病毒抗原的药物组合物及相关方法
WO2025171082A1 (en) * 2024-02-06 2025-08-14 Board Of Regents, The University Of Texas System Prefusion-stabilized hsv2 gb proteins
WO2025259931A1 (en) 2024-06-14 2025-12-18 Orbital Therapeutics, Inc. Compositions and methods for rna circularization
WO2026006203A2 (en) 2024-06-24 2026-01-02 Orbital Therapeutics, Inc. Compositions and methods for making circular rna
WO2026015882A1 (en) * 2024-07-12 2026-01-15 BioNTech SE Hsv antigen fragments and related methods
WO2026080379A1 (en) 2024-10-07 2026-04-16 Modernatx, Inc. Lyme disease mrna vaccines

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995027069A1 (en) * 1994-03-31 1995-10-12 Smithkline Beecham Biologicals (S.A.) Alphavirus rna as carrier for vaccines
US20040132683A1 (en) * 1989-03-21 2004-07-08 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate
WO2015005253A1 (ja) * 2013-07-08 2015-01-15 第一三共株式会社 新規脂質

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993001301A1 (en) * 1991-07-05 1993-01-21 The Penn State Research Foundation Mutant antiviral regulatory proteins
US7094767B2 (en) * 1994-07-22 2006-08-22 Merck & Co., Inc. Polynucleotide herpes virus vaccine
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US6214966B1 (en) 1996-09-26 2001-04-10 Shearwater Corporation Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
CA2270282A1 (en) * 1996-11-04 1998-05-14 Smithkline Beecham Corporation Novel coding sequences from herpes simplex virus type-2
US7390780B2 (en) * 1999-04-23 2008-06-24 Alza Corporation Gene delivery mediated by liposome-DNA complex with cleavable peg surface modification
HK1044799A1 (zh) * 1999-09-30 2002-11-01 University Of Washington 免疫学上重要的单纯疱疹病毒抗原
CN1254234C (zh) * 2000-06-09 2006-05-03 莱古伦公司 质粒dna(lipogenestm)和含细胞核定位信号/促融合肽缀合物的治疗剂包封到定向脂质体复合体中
US6998115B2 (en) 2000-10-10 2006-02-14 Massachusetts Institute Of Technology Biodegradable poly(β-amino esters) and uses thereof
US7708915B2 (en) 2004-05-06 2010-05-04 Castor Trevor P Polymer microspheres/nanospheres and encapsulating therapeutic proteins therein
ATE490267T1 (de) 2001-06-05 2010-12-15 Curevac Gmbh Stabilisierte mrna mit erhöhtem g/c-gehalt, kodierend für ein virales antigen
EP1412065A2 (en) 2001-07-27 2004-04-28 President And Fellows Of Harvard College Laminar mixing apparatus and methods
WO2003028657A2 (en) 2001-10-03 2003-04-10 The Johns Hopkins University Compositions for oral gene therapy and methods of using same
WO2003092665A2 (en) 2002-05-02 2003-11-13 Massachusetts Eye And Ear Infirmary Ocular drug delivery systems and use thereof
EP1713514B1 (en) 2004-01-28 2021-11-24 Johns Hopkins University Drugs and gene carrier particles that rapidly move through mucous barriers
US8241670B2 (en) 2004-04-15 2012-08-14 Chiasma Inc. Compositions capable of facilitating penetration across a biological barrier
EP1856179B1 (en) 2004-12-10 2013-05-15 Kala Pharmaceuticals, Inc. Functionalized poly (ether-anhydride) block copolymers
DE602006008625D1 (de) 2005-04-01 2009-10-01 Intezyne Technologies Inc Polymermicellen für die arzneistoffzufuhr
EP1885403B1 (en) 2005-04-12 2013-05-08 Nektar Therapeutics Poly(ethyleneglycol) conjugates of Lysostaphin
BRPI0611872B8 (pt) 2005-06-16 2021-05-25 Nektar Therapeutics reagente polimérico, conjugado, método para preparação de um conjugado e composição farmacêutica
WO2007070705A2 (en) * 2005-12-15 2007-06-21 The Trustees Of The University Of Pennsylvania Cationic lipid-mediated vectors
KR101513732B1 (ko) 2006-02-21 2015-04-21 넥타르 테라퓨틱스 분할된 분해가능한 폴리머 및 이로부터 제조된 컨주게이트
US8367113B2 (en) 2006-05-15 2013-02-05 Massachusetts Institute Of Technology Polymers for functional particles
WO2007134385A1 (en) * 2006-05-19 2007-11-29 The Walter And Eliza Hall Institute Of Medical Research Immunogenic compositions
EP2521786B1 (en) * 2006-07-20 2015-06-24 Vical Incorporated Compositions for vaccinating against hsv-2
DE602007012559D1 (de) 2006-09-08 2011-03-31 Univ Johns Hopkins H die schleimhaut
CA2671925A1 (en) 2006-12-21 2008-07-10 Stryker Corporation Sustained-release formulations comprising crystals, macromolecular gels, and particulate suspensions of biologic agents
US8877206B2 (en) * 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
EP2136788B1 (en) 2007-03-30 2011-10-26 Bind Biosciences, Inc. Cancer cell targeting using nanoparticles
ES2721850T3 (es) 2008-06-16 2019-08-05 Pfizer Nanopartículas poliméricas terapéuticas que comprenden alcaloides vinca y procedimientos de fabricación y uso de las mismas
JP2012501965A (ja) 2008-06-16 2012-01-26 バインド バイオサイエンシズ インコーポレイテッド 薬剤を装填したポリマーナノ粒子及びその製造方法と使用方法
US8613951B2 (en) 2008-06-16 2013-12-24 Bind Therapeutics, Inc. Therapeutic polymeric nanoparticles with mTor inhibitors and methods of making and using same
WO2010005740A2 (en) 2008-06-16 2010-01-14 Bind Biosciences, Inc. Methods for the preparation of targeting agent functionalized diblock copolymers for use in fabrication of therapeutic targeted nanoparticles
US20100087337A1 (en) 2008-09-10 2010-04-08 Bind Biosciences, Inc. High Throughput Fabrication of Nanoparticles
US20100216804A1 (en) 2008-12-15 2010-08-26 Zale Stephen E Long Circulating Nanoparticles for Sustained Release of Therapeutic Agents
JP5622254B2 (ja) 2009-03-31 2014-11-12 国立大学法人東京大学 二本鎖リボ核酸ポリイオンコンプレックス
WO2010127159A2 (en) 2009-04-30 2010-11-04 Intezyne Technologies, Incorporated Polymeric micelles for polynucleotide encapsulation
CA2816925C (en) 2009-11-04 2023-01-10 The University Of British Columbia Nucleic acid-containing lipid particles and related methods
ES2780156T3 (es) 2009-12-15 2020-08-24 Pfizer Composiciones terapéuticas de nanopartículas poliméricas con alta temperatura de transición vítrea o copolímeros de alto peso molecular
JP6175237B2 (ja) 2009-12-15 2017-08-02 ファイザー・インク コルチコステロイドを含む治療用ポリマーナノ粒およびそれを製造かつ使用する方法
JP5898627B2 (ja) 2009-12-15 2016-04-06 バインド セラピューティックス インコーポレイテッド エポチロンを含む治療用ポリマーナノ粒子ならびにそれを製造および使用する方法
ES2536429T3 (es) 2010-01-24 2015-05-25 Novartis Ag Micropartículas de polímero biodegradables irradiadas
WO2011106607A2 (en) * 2010-02-26 2011-09-01 Juvaris Biotherapeutics, Inc. Subunit vaccines for herpes viruses and methods of use
US8207290B2 (en) 2010-03-26 2012-06-26 Cerulean Pharma Inc. Methods and systems for generating nanoparticles
US20110262491A1 (en) 2010-04-12 2011-10-27 Selecta Biosciences, Inc. Emulsions and methods of making nanocarriers
US8802863B2 (en) 2010-05-24 2014-08-12 Sirna Therapeutics, Inc. Amino alcohol cationic lipids for oligonucleotide delivery
US20130196948A1 (en) 2010-06-25 2013-08-01 Massachusetts Insitute Of Technology Polymers for biomaterials and therapeutics
RS63817B1 (sr) * 2010-07-06 2023-01-31 Glaxosmithkline Biologicals Sa Čestice za isporuku slične virionu za molekule samoreplicirajuće rnk
US10307372B2 (en) 2010-09-10 2019-06-04 The Johns Hopkins University Rapid diffusion of large polymeric nanoparticles in the mammalian brain
JP2013544504A (ja) * 2010-10-11 2013-12-19 ノバルティス アーゲー 抗原送達プラットフォーム
EP2629760A4 (en) 2010-10-22 2014-04-02 Bind Therapeutics Inc THERAPEUTIC NANOPARTICLES CONTAINING COPOLYMERS OF HIGH MOLECULAR WEIGHT
WO2012061703A1 (en) 2010-11-05 2012-05-10 The Johns Hopkins University Compositions and methods relating to reduced mucoadhesion
WO2012099805A2 (en) 2011-01-19 2012-07-26 Ocean Nanotech, Llc Nanoparticle based immunological stimulation
JP6099573B2 (ja) * 2011-01-31 2017-03-22 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 新規なヘルペス抗原をコードする核酸分子、それを含むワクチン及びその使用方法
WO2012109121A1 (en) 2011-02-07 2012-08-16 Purdue Research Foundation Carbohydrate nanoparticles for prolonged efficacy of antimicrobial peptide
US9901554B2 (en) 2011-03-31 2018-02-27 Ingell Technologies Holding B.V. Biodegradable compositions suitable for controlled release
US9795679B2 (en) 2011-03-31 2017-10-24 Ingell Technologies Holding B.V. Biodegradable compositions suitable for controlled release
US8691750B2 (en) 2011-05-17 2014-04-08 Axolabs Gmbh Lipids and compositions for intracellular delivery of biologically active compounds
WO2012166923A2 (en) 2011-05-31 2012-12-06 Bind Biosciences Drug loaded polymeric nanoparticles and methods of making and using same
US20140141070A1 (en) * 2011-07-06 2014-05-22 Andrew Geall Liposomes having useful n:p ratio for delivery of rna molecules
JP6018197B2 (ja) 2011-07-21 2016-11-02 クローダ インターナショナル パブリック リミティド カンパニー 分枝状ポリエーテル−ポリアミドブロックコポリマー並びにそれらの製造方法及び使用方法
WO2013032829A1 (en) 2011-08-26 2013-03-07 Arrowhead Research Corporation Poly(vinyl ester) polymers for in vivo nucleic acid delivery
CA2845845A1 (en) 2011-08-31 2013-03-07 Mallinckrodt Llc Nanoparticle peg modification with h-phosphonates
EP2747761A1 (en) 2011-09-22 2014-07-02 Bind Therapeutics, Inc. Methods of treating cancers with therapeutic nanoparticles
WO2013072929A2 (en) 2011-09-23 2013-05-23 Indian Institute Of Technology Nanop article based cosmetic composition
BR112014008694A2 (pt) * 2011-10-11 2017-06-20 Novartis Ag moléculas de ácido nucleico policistrônico recombinante
JP6294229B2 (ja) 2011-10-18 2018-03-14 ダイセルナ ファーマシューティカルズ， インコーポレイテッドＤｉｃｅｒｎａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． アミン陽イオン性脂質およびその使用
KR102451116B1 (ko) 2011-10-27 2022-10-06 메사추세츠 인스티튜트 오브 테크놀로지 약물 캡슐화 마이크로스피어를 형성할 수 있는, ｎ-말단 상에 관능화된 아미노산 유도체
WO2013078199A2 (en) 2011-11-23 2013-05-30 Children's Medical Center Corporation Methods for enhanced in vivo delivery of synthetic, modified rnas
CN104114572A (zh) * 2011-12-16 2014-10-22 现代治疗公司 经修饰的核苷、核苷酸和核酸组合物
CA2863632C (en) 2012-01-19 2017-07-11 The Johns Hopkins University Nanoparticle formulations with enhanced mucosal penetration
WO2013113326A1 (en) * 2012-01-31 2013-08-08 Curevac Gmbh Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
US9416090B2 (en) 2012-02-03 2016-08-16 Rutgers, The State University Of New Jersey Polymeric biomaterials derived from phenolic monomers and their medical uses
US20150337068A1 (en) 2012-02-10 2015-11-26 Karl K Berggren Preparation, purification and use of high-x diblock copolymers
WO2013143555A1 (en) * 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
AU2013243948A1 (en) * 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with human disease
US10245229B2 (en) * 2012-06-08 2019-04-02 Translate Bio, Inc. Pulmonary delivery of mRNA to non-lung target cells
WO2014093924A1 (en) * 2012-12-13 2014-06-19 Moderna Therapeutics, Inc. Modified nucleic acid molecules and uses thereof
EP4331620A3 (en) * 2012-12-07 2024-12-04 Translate Bio, Inc. Lipidic nanoparticles for mrna delivery
DK2970456T3 (da) * 2013-03-14 2021-07-05 Translate Bio Inc Fremgangsmåder og sammensætninger til levering af mrna-kodede antistoffer
WO2014152030A1 (en) 2013-03-15 2014-09-25 Moderna Therapeutics, Inc. Removal of dna fragments in mrna production process
WO2014152031A1 (en) 2013-03-15 2014-09-25 Moderna Therapeutics, Inc. Ribonucleic acid purification
WO2014144767A1 (en) 2013-03-15 2014-09-18 Moderna Therapeutics, Inc. Ion exchange purification of mrna
WO2014152027A1 (en) 2013-03-15 2014-09-25 Moderna Therapeutics, Inc. Manufacturing methods for production of rna transcripts
US10130649B2 (en) * 2013-03-15 2018-11-20 Translate Bio, Inc. Synergistic enhancement of the delivery of nucleic acids via blended formulations
WO2014144711A1 (en) 2013-03-15 2014-09-18 Moderna Therapeutics, Inc. Analysis of mrna heterogeneity and stability
US20160032273A1 (en) 2013-03-15 2016-02-04 Moderna Therapeutics, Inc. Characterization of mrna molecules
SG10201912038TA (en) * 2014-04-23 2020-02-27 Modernatx Inc Nucleic acid vaccines
WO2018226638A1 (en) * 2017-06-05 2018-12-13 The Brigham And Women's Hospital, Inc. Vero cell lines stably expressing hsv icp0 protein

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040132683A1 (en) * 1989-03-21 2004-07-08 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate
WO1995027069A1 (en) * 1994-03-31 1995-10-12 Smithkline Beecham Biologicals (S.A.) Alphavirus rna as carrier for vaccines
WO2015005253A1 (ja) * 2013-07-08 2015-01-15 第一三共株式会社 新規脂質

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ADV GENET, vol. 89, JPN6020027009, 2014, pages 179 - 233, ISSN: 0004312097 *
CLIN MICROBIOL REV, vol. 16, no. 1, JPN6021031724, 2003, pages 96 - 113, ISSN: 0004723912 *
JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY, vol. Vol.72, No.9, SUPPL.1, JPN7021000116, 2014, pages 107 - 98, ISSN: 0004426331 *
PEDIATRIC BLOOD AND CANCER, vol. Vol.62, Supplement 2, JPN7021000117, June 2015 (2015-06-01), pages 24 - 4012, ISSN: 0004426332 *

Also Published As

Publication number Publication date
EP3365009A4 (en) 2019-07-03
WO2017070623A1 (en) 2017-04-27
AU2016342049A1 (en) 2018-06-07
JP2022037134A (ja) 2022-03-08
EP3365009A1 (en) 2018-08-29
AU2016342049B2 (en) 2023-05-18
US20180303929A1 (en) 2018-10-25
TN2018000155A1 (en) 2019-10-04
IL258833A (en) 2018-06-28
CA3002822A1 (en) 2017-04-27
US20240173400A1 (en) 2024-05-30
SG11201803365RA (en) 2018-05-30
CO2018005258A2 (es) 2018-11-22
EA201890999A1 (ru) 2018-12-28
CN108472355A (zh) 2018-08-31
MX2018004918A (es) 2019-04-01
CL2018001056A1 (es) 2018-10-19
AU2023216825A1 (en) 2023-09-07
BR112018008090A2 (pt) 2018-11-13
PE20181531A1 (es) 2018-09-26
PH12018500855A1 (en) 2018-10-29
KR20180096593A (ko) 2018-08-29
MA46024A (fr) 2019-07-03

Similar Documents

Publication Publication Date Title
US20230346907A1 (en) Sexually transmitted disease vaccines
US20250188132A1 (en) Nucleic acid vaccines for varicella zoster virus (vzv)
US11918644B2 (en) Varicella zoster virus (VZV) vaccine
US20250099569A1 (en) Respiratory syncytial virus vaccine
US11752206B2 (en) Herpes simplex virus vaccine
JP2022037134A (ja) 単純ヘルペスウイルスワクチン
US20200054737A1 (en) Herpes simplex virus vaccine
JP2025041835A (ja) 呼吸器合胞体ウイルスワクチン
JP2021175745A (ja) ヒトサイトメガロウイルスワクチン

Legal Events

Date Code Title Description
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20181010

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20181015

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191021

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191021

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200703

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20200703

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20200715

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200727

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210118

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210419

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210716

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210816

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211216

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20211216

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20220104

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220208

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220214

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20220311

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20220322

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20221212

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20230116

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230417

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230718

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231128